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INTRODUCTION 
It is our objective in this paper to highlight recent discoveries and developments 
concerning "new" immunosuppressive drugs. Our intention it not to provide an 
all-encompassing, detailed review of the overwhelming number of experimental 
findings concerning these biochemically diverse agents which have recently been 
published. Many of these observations have been surveyed recently under the 
title of individual drugs (see Table I for references) and have also been reviewed 
in this volume. Rather, we have chosen, albeit subjectively, to illustrate a number 
of important recent contributions which research on these agents has made, first, 
to our understanding of lymphocyte cell biology, second, to the improvement 
of immunosuppressive therapy, particularly in the context of organ and tissue 
transplantation and, third, to our awareness of immunological phenomena which 
underlie and may be crucial for the acceptance of organ transplants. 
MECHANISMS OF ACTION OF NEW IMMUNOSUPPRESSIVE DRUGS 
What CsA, FK 506 and rapamycin have told us about molecular events underlying 
lymphocyte activation and degranulation: calcineurin and protein kinases as import-
ant signaling mediators 
Whilst our understanding of the molecular events that lead to immune cell 
activation has improved enormously in recent years, we remain quite ignorant of 
The Pittsburgh Transplantation Institute and the Departments of Surgery and Molecular 
Genetics & Biochemistry, University of Pittsburgh Health Science Center, Pittsburgh, 
Pennsylvania, USA. 
Correspondence: Dr. A. W. Thomson, The Pittsburgh Transplantation Institute, University 
of Pittsburgh, W1544 Biomedical Science Tower. Terrace and Lothrop Street, Pittsburgh. 
PA 15213, U.S.A. 
72 THOMSON & STARZL 
the precise sequence of events that leads from antigen recognition to lymphocyte 
activation and cell proliferation. Recent revelations, however, concerning the 
molecular actions of cyclosporin A (esA) and the new immunosuppressive drugs, 
FKS06 and rapamycin, have provided important new information on the bio-
chemical processes which regulate these events. Of special significance has been 
the realization that none of these T-cell directed immunosuppressants (CsA, 
FKS06 or rapamycin) is, by itself, antilymphocytic. Rather, these molecules are 
now perceived as "molecular adaptors" which serve to mediate the interaction 
between their respective intracellular drug-binding proteins (or "immunophilins") 
and their individual target molecules. Vigorous research on the mode of action 
of FKS06 and CsA (Liu et al. 1991, Liu 1993) has revealed that the heterodimeric, 
Ca2+ I calmodulin-regulated phosphatase calcineurin is a major common target of 
the CsA-cyclophilin A and FKS06-FKS06 binding protein 12 (FKBPI2) drug-
immunophilin complexes in vitro (cyclophilin A and FKBP12 are the predominant 
immunophilin isoforms that bind CsA and FKS06, respectively). Although rapa-
mycin, which is similar structurally to FKS06, also binds to FKBP, it fails to 
inhibit ealcineurin and acts by a quite distinct molecular mechanism (see below). 
It has been discovered that calcineurin is a key enzyme in the T-cell signal 
transduction cascade following T-cell receptor (TCR) activation (Clipstone & 
Crabtree 1992, 1993, Liu et al. 1992, O'Keefe et a1. 1992, Fruman et a1. 1992). 
Furthermore, it is now established that inhibition of calcineurin phosphatase 
activity, and not CsA affinity for cyclophilin A, correlates with the suppression 
of early T-cell activation events (Nelson et al. 1992). Several of the key immuno-
logical findings concerning calcineurin are summarized in Table II. Amongst the 
most important conclusions from these observations is that interaction of drug-
immunophilin complexes with calcineurin and inhibition of its phosphatase activ-
ity provides a molecular basis for the inhibitory effect of CsA or FKS06 on 
expression of genes encoding T-cell growth factor (interleukin-2; TL-2) and other 
cytokines. 
Since both CsA and FK506 inhibit specifically the TCR-mediated transcription 
of the IL-2 gene, its promotor region, and in particular the binding site for the 
nuclear factor of activated T cells (NFAT), has been the focus of intensive 
investigation. NFAT is a T-cell specific transcription factor, the activity of which 
correlates with the extent of IL-2 gcne transcription following activation of the 
TCR. NF-AT has two components - a nuclear (n) subunit (NF-ATn) and a 
cytoplasmic (c) component (NF-ATc). A key observation reported by Crabtree 
and his colleagues is that the CsA/FKS06 drug-immunophilin complexes, which 
form pentameric complexes with calcineurin (A and B) and calmodulin (see Fig. 
1), block the assembly of functional NF-AT (Flanagan et al. 1991). This appears 
to be achieved by inhibition of the translocation of the pre-existing NF-ATc from 
the cytoplasm to the nucleus. NF-ATn is transcriptionally inactive in all cells other 
than activated T cells and is induced by signals from the TCR. Its appearance is 
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TABLE II 
The immunological significance of calcineurin (sec also Fig. 1) 
I. Calcineurin is a key rate-limiting en7yme in T-cell signal transduction and mediator of 
Ca' + -dependent events. 
2. lL-2 production in T cells activated via the TCR/CD3 complex correlates closely with 
the level of caleineurin activity. 
3. Cells expressing low levels of caleinenrin (e.g. T cells) are most sensitive to CsA/FKS06. 
4. Overexpression of caleineurin overcomes the CsA/FKS06-mediated inhibition of NF-
AT-dependent cytokine gene transcription. 
5. Immunosuppressive activity of cyclosporin analogues correlates with inhibition of cal-
cineurin phosphatase activity. 
6. Caleincnrin is involved in signalling events that lead to degranulation of cytotoxic T-
cells. 
7. Calcineurin activity plays a key role in TCR/CD3-l11ediated induction of apoptosis in 
T-cell hybridomas. 
For further details the reader is referred to recent papers and reviews (Schreiber & Crabtree 
1992, Fruman et al. 1993, Clipstone & Crabtree 1992,1993). 
not blocked by FK506 or CsA. Current thinking is that FK506 and CsA block 
the dephosphorylation by calcineurin of NF-ATc, a step that is required for its 
translocation to the nucleus. This model has gained credence from the finding of 
McCaffrey et al. (l993) that NF-ATc is indeed a phosphoprotein in resting T 
cells and can be dephosphorylated by calcineurin. Moreover, this group has also 
shown that dephosphorylation of NF-ATc by calcineurin in cell lysates can be 
inhibited by a specific peptide inhibitor of calcineurin or by pre-treatment of the 
cells with CsA or FK506. These data suggest both that NF-ATc may be the direct 
substrate of calcineurin and that it may serve as the ultimate protein messenger 
of the signal transduction cascade from the cell surface TCR to the nucleus. 
A role for calcineurin has also been suggested recently in the degranulation of 
(murine) cytotoxic T cells (Outz et al. 1993). Thus, in addition to its role in 
cytokine gene expression, calcineurin also seems to be involved in T-cell activation 
processes (e.g. those which precede degranulation) that do not require protein 
synthesis. Clearly, much insight has been gained into the influence of CsA and 
FK506 on signal transduction in T cells. It is to the suppressive action of these 
drugs on IL-2 synthesis by T cells that their capacity to inhibit organ allograft 
rejection is ascribed. A complementary and! or alternative mechanism, however, 
has been proposed for the immunosuppressive action ofCsA (Erlanger 1993). This 
is based on the finding that CsA inhibits the chemotactic activity of extracellular 
cyclophilin for inflammatory leukocytes (Xu et al. 1992). In sharp contrast to these 
concepts of drug action, much less is known about the molecular mechanisms that 
underlie the neuro- and nephrotoxic properties of CsA and FK506. It is in this 
area that improved understanding will be essential for the future design of more 
specific and less toxic immunosuppressants. 
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Figure 1. The T-cell receptor-mediated signal transduction pathway leading to interleukin-
2 (IL-2) transcription with the recently identified signal-transducing molecules highlighted. 
PLC: phospholipase Cj'l; IP): inositol-I,4,5-triphosphate; NF-ATc: the cytoplasmic compo-
nent of the nuclear factor of activated T cells; NF-ATn: the nuclear component of NF-AT; 
FKBP: FK506 binding protein. Reproduced from Liu J., Immunology Today 14, 293, 1993 
with kind permission of the author and Elsevier Science Publishers Ltd. 
In T cells, activation of the genes for both IL-2 and its receptor determines 
the progression of the cell from the GO to the GI phase of the cell cycle. GI-
to-S progression is then regulated by IL-2. The powerful immunosuppressant 
rapamycin is a close structural analogue of FK506 and binds to the same immuno-
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philin (FKBP) as FK506, forming a drug-immunophilin (rapamycin-FKBP) com-
plex (Schreiber 1991). This complex, however, does not block calcineurin activity 
(Liu et al. 1991) or GO-to-Gl progression, as defined by the expression of IL-2 
or its receptors. It has recently been discovered that rapamycin potently inhibits 
the rapid activation of p70S6 kinase following IL-2 stimulation of T cells and, 
consequently, Gl-to-S phase progression (Price et al. 1992, Kuo et al. 1992, 
Chung et al. 1992). Although this finding has implicated p70S6 kinase activation 
as important in Ca2+ -independent signaling leading to cell proliferation, there is 
no evidence that p70S6 kinase is involved directly in S-phase entry. On the other 
hand, recent results obtained using the murine helper T-cell clone DIO, have 
demonstrated that the IL-2-stimulated expression of a serine/ threonine kinase 
p34 cdc2, that is known to be required for cell cycle progression and may be 
essential for G l--S transition, is a target of rapamycin (Flanagan & Crabtree 
1993). 
Fig. 2 depicts a model for the action of rapamycin. In this model (for further 
Target of Rapamycin (Tor) 
Growth factor receptor 
Tor ---.f\ p70S6 kinase 
c-jun 
c-myc 
cyclins 02&03 
cdk2 
cyclin E 
, 
Activation 
genes for: 
c-myb 
cyclin A 
cdc2 
----Tor-de pen den t 
s 
Figure 2. A model for the mechanism of action of rapamycin. IL-2-mediated signalling 
activates two distinct pathways: a target of rapamycin (Tor)-independent pathway and a 
Tor-dependent pathway. The Tor-dependent pathway is simply defined as being inhibited 
by rapamycin. Rapamycin blocks cell-cycle progression at a point where many early to 
mid-G 1 cell-cycle regulatory proteins have accumulated (cyclins D2, D3 and E) yet are 
unable to execute their function without an additional triggering event(s). The activation 
of the cyclin E/CDK2 kinase complex, which is blocked by rapamycin, could be the 
triggering event required for progression into the S phase of the cell-cycle. After Flanagan 
et al. (1993). 
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information see Flanagan & Crabtree 1993, and Flanagan et al. 1993), IL-2 
signalling via the IL-2 receptor activates both Target of rapamycin (Tor)-indepen-
dent and Tor-dependent pathways. Rapamycin is thought to block G l--->S pro-
gression at a point where many early to mid-G I cell cycle regulatory proteins 
(cyclins 02, D3 and E) have accumulated, yet cannot fulfil their function without 
additional triggering events. Activation of the cyclin E/cdk2 complex, which is 
blocked by rapamycin, may be the triggering event required for progression into 
S-phase. Undoubtedly, rapamycin provides a valuable tool for analysis and link-
age of these autocrine growth factor receptor-induced signalling events to down-
stream targets which regulate S-phase entry. The reliance of T lymphocytes on a 
single (IL-2-IL-2R) signalling pathway renders these cells uniquely susceptible to 
rapamycin. 
The discovery of ca1cineurin and p70S6 kinases as important signaling me-
diators clearly emphasizes the utility of immunosuppressive drugs as probes of 
lymphocyte signal transduction. 
Lejlllnomide resembles rapamycin in illhibiting T-cell responses to IL-2 
Leflunomide is a novel isoxazol derivative with potent immunosuppressive ac-
tivity that is unrelated chemically to CsA, FK506 or rapamycin (Chong et a1. 
1993, Xiao et al. 1993). It prevents acute rejection of kidney, heart and skin 
allografts in the rat at doses similar to those of CsA. Unlike CsA, however, 
leflunomide can reverse ongoing acute rat cardiac allograft rejection. In vitro, 
leflunomide is considerably less potent than CsA; 50 tiM is the ICso required 
for inhibition of the mixed lymphocyte reaction, compared with 45 n M for 
CsA or InM for rapamycin (Chong et a1. 1993). Since leflunomide is unre-
lated structurally to any other immunosuppressive drug, its mechanism of ac-
tion is at present unknown. Recently, leflunomide has been shown to have no 
effect on the induction of IL-2R expression on activated human T cells. How-
cver. it partially reduces IL-2 production by and completely inhibits prolifer-
ation of T cells stimulated with either anti-C03 plus phorbol myristate acetate 
(PMA) or (unlike CsA or FK506) anti-CD28 monoclonal antibody plus PMA 
(Chong et al. 1993). Thus. leflunomide resembles rapamycin in that both 
agents suppress T-cell proiireration, principally by inhibition of T-cell respon-
sivencss to IL-2. It is noteworthy that rapamycin has already been shown to 
act synergistically with CsA (both at subtherapeutic or minimally effective 
doses; see below). Leflunomide therefore joins both rapamycin and mono-
clonal anti- IL-2R antibodies as a promising experimental agent for combi-
nation immunosuppressive therapy with CsA, each agent affecting distinct 
phases of the important IL-2-IL-2R T-cell signal transduction pathway. 
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OTHER INSIGHTS 
Inhibition of cytokine and growth factor action by rapamycin in vivo may inhibit 
vascular injury foUOlving allostimulatiol1 
Rapamycin exhibits the capacity not only to inhibit the growth of T lymphocytes 
but also the prolifertion of hepatocytes, endothelial cells, fibroblasts and smooth 
muscle cells stimulated by "non-immune" growth factors, such as hepatocyte 
growth factor, epidermal growth factor and fibroblast growth factor beta (Morris 
1992, Francavilla et al. 1991, Akselband et al. 1991). Inhibition of paracrine 
cytokine effects by rapamycin could suppress, indirectly, additional growth factor 
production. In all types of vascular injury, inflammation and the release of 
cytokines and growth factors cause luminal narrowing. Recently, Gregory et al. 
(1993) have made important observations on the influence of rapamycin on 
arterial intimal thickening (a major complication that limits long-term survival 
after heart transplantation). In their experimental rat model, vascular injury 
was caused by either alloimmune stimulation (femoral artery allografting) or 
mechanical (balloon catheter) damage. They found inhibition of intimal prolifer-
ation in arteries by rapamycin. This effect was ascribed to interference by rapamy-
cin with cytokine and growth factor actions that attract and activate macrophages 
and cause smooth muscle cells to migrate and proliferate. Although mRNAs for 
growth factors were expressed extensively ill situ, intimal thickening was reduced 
compared with injured vessels from untreated control rats. These in vivo obser-
vations are entirely in line with the in ritro selective inhibitory effects of rapamycin 
on cytokine / growth factor action and may have significant therapeutic impli-
cations for the influence of rapamycin on vascularized organ allograft survival. 
Macrolide immunosuppressants (FK506 (Jnd rapamycin) may exhibit differential 
inteljerence with cytokille gene expressio/1 in vitro or in vivo 
Two subsets of murine CD4 + T cells (T HI and T H2) have been identified on the 
basis of their cytokine secretion and functional profiles (Mosmann & Coffman 
1989) and there is growing evidence for such human functional subsets. T HI cells 
produce IL-2, IFN-y, and TNF,B, whereas TH2 cells secrete IL-4, IL-5, IL-IO and 
IL-13, but not I L-2 or IFN-y. There is also evidence that, in vitro, FK506 
may spare expression of the anti-flammatory cytokine IL-IO (cytokine synthesis 
inhibitory factor) by cloned murine Tile cells, whilst suppressing concomitant IL-
4 mRNA production (Wang et al. 1991). Thus, differential interference with 
cytokine gene expression and crossregulation ofTH, cell (IL-2 and IFN-y produc-
tion) may be important mechanisms whereby FK506 inhibits immune cell acti-
vation and maintains immunosuppression in vivo. 
There is also evidence from recent studies in the rat that rapamycin administra-
tion can result in the divergent transcription of distinct cytokine genes in vivo. 
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The model used was accelerated cardiac allograft rejection in sensitized animals. 
The findings concern the influence of rapamycin on the early expression of genes 
encoding cytokines with IL-8-like neutrophil activation/ chemotactic properties. 
I n addition, the later expression of T H 1- and T Hr specific cytokines, IFN -;' and 
I L-\ 0 respectively, was examined (Wieder et al. 1993). Quite novel intra-transplant 
effects of rapamycin were observed. Thus, rapamycin inhibited IL-8-like mRNA/ 
protein production, with subsequent suppression of graft neutrophil infiltration. 
Till-specific IFN-y mRNA was also inhibited. In contrast, there was simultaneous 
sparing of T H2-specific IL-IO mRNA. These findings suggest that the divergent 
transcription of distinct cytokine genes may contribute to the immunosuppressive 
efficacy of rapamycin in sensitized transplant recipients. It is also intriguing that, 
whereas rapamycin does not inhibit IFN-y production by activated T cells in 
vitro, it suppresses IFN-y mRNA/protein production in this in vivo model. Taken 
together, these in vitro and in vivo studies show that two potent anti-T cell agents 
(rapamycin and FKS06), with distinct molecular actions, spare IL-10 expression 
whilst suppressing the production of pro-inflammatory cytokines. 
Rapmnl'cin inhibits cytokine-indllced immunoglohulin production in vitro, but fails 
to slippress humoral immunity in presensiti::ed illdil'iduals 
It is well-recognized that rapamycin is about IOOO-foid more potent than esA in 
inhibiting spontaneous or pokeweed mitogen (PWM)-stimulated immunoglobulin 
(Ig) production by human PBMC in vitro. The drug abolishes T-cell help to T-
dependent Ig production and also directly suppresses Ig production by pure B 
cells stimulated with IL-2 and Staphylococcus aureus Cowan 1 (SAC). Luo et al. 
(1993) have also shown that neither IL-2, IL-4, IL-6 nor IFN-y was able to 
reverse the inhibitory effect of rapamycin in unstimulated or PWM-stimulated 
PBMC. These observations show that both T and B cells are direct targets of 
rapamycin. These in vitro studies suggest that rapamycin may be useful in the 
treatment of presensitized transplant patients with high titers of antibody that 
normally preclude transplantation. Other in vivo studies, however, have shown 
that rapamycin does not significantly suppress humoral immunity (alloantibody 
synthesis) in rats with established humoral alloreactivity (Propper et al. 1992). 
Synergy between rapamycin and CsA 
Mutually synergistic interactions between rapamycin and CsA have been reported 
both in vitro and in vivo (Kimball et al. 1991, Kahan et al. 1991b). In vitro, 
rapamycin augments the inhibitory effects of CsA on human PBL activation by 
PHA, anti-CD3 monoclonal antibody, and the MLR. Rapamycin also enhances 
the capacity of CsA to suppress cytotoxic T-cell generation and precursor fre-
quency during alloactivation in vitro. Moreover, CsA potentiates the inhibitory 
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effects of rapamycin on the proliferation of IL-2- and IL-6-dependent cell lines 
(Kahan et a1. 1991 b). At the same time, antagonism between low doses of FK506 
and CsA can be demonstrated, using the same experimental in vitro systems. 
In vivo, a strong synergistic immunosuppressive effect of low doses of rapamy-
cin and CsA has been reported by Kahan et a1. (l991a), using the Buffalo-> Wistar 
Furth rat cardiac allograft model. Thus, minimally effective doses of rapamycin 
(0.02 mg/kg i.v.) and CsA (2 mg/kg p.o.), when combined, allowed 100';', cardiac 
gran survival beyond 50 days in all graft recipients. Evidence has also been cited 
(Kahan et al. 1991a) of combined rapamycin/CsA/RS-61443 (mycophenolate 
mofetil) treatment prolonging mouse heart allograft survival from 18 to 140 days. 
Morris et a1. (I991a) have also reported that the combination of rapamycin with 
FK506 acts synergistically to prolong mouse heart allograft survival. The latter 
data are particularly interesting as they are not consistent with reports that 
rapamycin and FK506 are reciprocal antagonists with respect to T-cell activation 
in vitro. This appearent discrepancy may be explained by differing relative concen-
tration levels of the two drugs. In vitro, a 100-fold molar excess of one drug 
relative to the other is required for exhibition of antagonism. 
OTHER DRUGS 
S'K&F 105685: an inducer o/Ilon-specific splenic suppressor cells follmdng experi-
mental cardiac transplantatio/l 
SK&F 105685 is a novel azaspirane which suppresses autoimmune disorders in 
experimental animals. It is also effective, both in short-term pretreatment or 
treatment, in prolonging cardiac allograft rejection in the rat. Studies by Schmid-
bauer et a1. (1993) have shown that, in this animal model, SK&F 105685 sup-
presses the graft cellular infiltrate and the induction of IL-2R and abolishes IL-
2 and IFN-y production. Adoptive transfer of spleen cells from SK&F 105685-
treated, allografted donors to naive recipients significantly prolonged the survival 
of donor-specific or third-party cardiac allografts. A search for the identity of 
the cells conferring this inhibitory effect revealed that, unlike classic CD8' sup-
pressor T cells, the SK&F I05685-induced cells did not exhibit characteristics of 
mature, T, B, NK cells or macrophages but may belong to the premyeloidl 
monocytic lineage (Schmidbauer et a1. 1993). They were also similar to "natural 
suppressor" cells previously generated in experimental animals by total lymphoid 
irradiation. Significantly, no other class of immunosuppressive drugs with a 
similar immunopharmacologic profile to SK&F 105685 has been described. It 
will be of interest to determine whether SK&F 105685 exhibits synergistic interac-
tions with CD4 T cell-directed immunosuppressive therapy using CsA or FK506 
in rat allograft models. It is promising that there is already evidence of at least 
additive immunosuppressive effects with subtherapeutic doses of CsA (Schmid-
bauer et a1. 1993). 
• 5 
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RS-61443 (mycophenolate mofetil) facilitates tolerance induction by a CsA-
sensitive mechanism 
81 
Mycophenolate mofetil (MM) is a pro-drug of the antiproliferative agent myco-
phenolic acid (MPA). It specifically and reversibly inhibits inosine monophos-
phate dehydrogenase, thus depleting guanosine and deoxyguanosine nucleotides. 
Since both T and B cells are more dependent on de novo purine biosynthesis than 
other cells, MPA has a T- and B-lymphocyte-selective antiproliferative effect, 
both in vitro and in vivo (for reviews see Sollinger et a1. 1991, Allison & Eugui 
1993). MM inhibits vascularized organ allograft rejection in animals (Sollinger 
et a1. 1991). The drug may be superior to azathioprine in preventing early human 
rcnal allograft rejection because of a higher therapeutic index (Sollinger et a1. 
1992). Significantly, MM can reverse ongoing rejection, even when OKT3 and 
high-dose steroids have failed. Interestingly, and in common with many other 
immunosuppressive drugs with diverse modes of action, short-term treatment of 
rodents with MM induces tolerance to cardiac allografts (Morris et a1. 1991 b). 
MM treatment also facilitates the induction of indefinite, donor-specific tolerance 
to pancreatic islet allografts in the mouse. Hao et al. (1992) have reported that 
this latter phenomenon is an active form of tolerance. rather than clonal deletion 
or anergy and that it can be inhibited by CsA administered in combination with 
MM. The mechanism underlying this antagonism between CsA and MM remains 
to be elucidated. 
RS-61443 (mycophenolate mofetil) interferes with natural antibody production 
and adhesion molecule glycosylation 
M M seems to be an important new drug for clinical use, because of its low in 
rim toxicity (unlike CsA and FKS06, it is not potentially nephrotoxic). Moreover, 
even chronic administration of MM in human patients or experimental animals 
does not appear to increase susceptibility to infections (Platz et al. 1991. Sollinger 
ct a1. 1991). Two other recent observations underscore its potential value in the 
control of organ transplant rejection. First, natural antibodies are considered a 
key element in initiating the hyperacute rejection of discordant organ xenografts. 
The currently available approaches for the depletion of natural antibodies (such 
as plasmaphercsis or immunoabsorption by organ perfusion) although effective, 
have only a very temporary effect. Any agent which can effectively control the 
production of natural antibody may prove valuable in the management of xeno-
graft rejection. It is thus of potential importance that, in addition to inhibiting 
humoral immune responses to a variety of antigens. MM has now been shown 
to reversibly inhibit the return of JgM natural antibody to the circulation after 
its acute depletion (Figueroa et a!. 1993). A rebound in antibody production was, 
however. encountered following cessation of the drug on day 14. Conceivably, 
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depletion of natural antibody for a significant period after discordant xenotrans-
plantation using MM or other anti-B cell agents may spare the vascular endo-
thelium of the graft from the injurious effects of antibody and complement, 
enhancing the chances of "accomodation" of the xenografted organ. 
One of the important metabolic effects of guanine triphosphate depletion 
mediated by MP A may be decreases in the transfer of mannose and fucose to 
glycoproteins, including adhesion molecules with lectin-like domains. These in-
clude selectins (e.g. E-selectin), which facilitate the attachment of leukocytes to 
endothelial cells and to target cells (Allison 1992). It has been postulated that, 
by this mechanism, MPA could inhibit the recruitment of neutrophils, lympho-
cytes and monocytes to sites of inflammation, including those of rejecting vascu-
larized organ allografts. 
The immunosuppressive action of Brequinar sodium and its potentiation by cytidine 
Another important new anti-proliferative drug is Brequinar sodium (BQR) 
(Makowka & Cramer 1992). Tn inhibits de novo pyrimidine biosynthesis, and 
consequently both DNA and RNA synthesis, by blocking the activity of dihyd-
roorotate dehydrogenase. Since BQR is known to prevent the synthesis of nucleo-
tides during cell proliferation, we hypothesized that it would be highly effective 
in controlling strong lymphocyte proliferative responses, but might be less effec-
tive in controlling comparatively weak responses that do not necessarily involve 
new nucleotide synthesis. This question was addressed by us using cultured murine 
spleen cells in the presence of different stimuli, including Con A, PMA± 
ionomycin, anti-CD3 monoclonal antibodies and anti-Ig. 
The addition of BQR (0.001 to 10 ,ug/ml) at the start of a 72-hour culture 
period caused dose-dependent inhibition of strong proliferative responses, induced 
either by Con A (5 ,ug/ml) or PMA + ionomycin. A residual degree of proliferation 
persisted, however, even at the highest BQR concentrations. In contrast, no 
impairment of low concentration Con A (0.5 or 0.1 ,ug/ml), anti-CD3, or anti-
Tg-induced responses was observed. In order to ascertain its role in arresting 
nucleotide synthesis, we attempted to reverse the inhibitory effect of BQR by 
adding exogenous uridine or cytidine to lymphocyte cultures. The inhibitory 
activity of BQR was reversed completely by adding uridine at 0.1 mM (Thomson 
et a1. 1993). In contrast, the combination of BQR and cytidine potentiated the 
action of BQR and abrogated anti-CD3 or anti-Tg-induced lymphocyte prolifer-
ation in a dose-dependent manner. A synergistic inhibitory action between BQR 
and cytidine was observed when the BQR concentration was higher than 0.1 Jlgi 
ml and with cytidine at 0.1 mM (Thomson et al. 1993). It was found that the 
production of IL-2 and IL-4 was only slightly affected by BQR, but was signifi-
cantly suppressed by coadministration of BQR and cytidine. Neither BQR on its 
own, however, nor the combination of BQR with cytidine affected production of 
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mRNA for IL-2, IL-4 or IFN-y, as determined by the polymerase chain reaction 
(Woo et al. 1993a). These novel observations suggest that BQR may not only 
affect dihydroorotate dehydrogenase activity, but may also inhibit the enzyme 
cytidine deaminase which convents cytidine to uridine (see Fig. 3 for a proposed 
model for the sites of action of BQR). 
The antimetabolic effects of BQR complement the well-known cytokine syn-
thesis inhibitory actions ofFK506 or esA. The combination ofBQR and cytidine, 
however, offers a further possibility for inhibition of both cytokine production 
and T- and B-cell proliferation. Indeed, we have also shown recently that BQR 
inhibits IL-6-induced differentiation of human B cells into IgM-secreting plasma 
cells (Tamura et al. 1993). This effect was also potentiated by cytidine (but 
reversed by uridine). Based on these observations, the combination of BQR and 
cytidine may have potential for the control of graft rejection. Indeed, we have 
presented preliminary data which show that cytidine potentiates the inhibitory 
Dihydroorotate 
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Figure 3. Structure of brequinar sodium (BQR) superimposed on a flow diagram to indicate 
the probable sites of action of the drug on pyrimidine biosynthesis. Sites of enzyme 
action are denoted by numbers in parentheses. In addition to inhibiting dihydroorotate 
dehydrogenase, our recent observations indicate that BQR also inhibits cytidine deaminase. 
The enzymes involved in the pathway are (1) dihydroorotate dehydrogenase; (2) orotate 
phosphoribosyltransferase, orotidine Y - monophosphate decarboxylase, nucleoside mono-
phosphate kinase and nucleoside disphosphate kinase (in sequence along the pathway); (3) 
nucleoside kinase; (4) cytidine deaminase and (5) CTP synthetase. CTP=cytidine triphos-
phate; UTP = uri dine triphosphate. 
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effect on BQR on hamster cardiac xenograft rejection in the rat (Woo et ai. 
1993b). 
Deoxyspergualin (DSG) inhibits cell maturation 
The semi-synthetic polyamine lS-deoxyspergualin (DSG) exhibits a novel spec-
trum of immunosuppressive activity in experimental animals and is effective both 
in allogeneic and xenogeneic transplantation models in non-human primates 
(Morris 1991, Suzuki 1993). It is effective (either alone or in combination with 
other agents) as rescue therapy in human renal transplantation (see below). 
Although elucidation of the mode of its action in vitro has been slow, it is 
evident that DSG may affect monocyte/macrophage function predominantly, 
including inhibition of oxidative metabolism, lyosomal enzyme synthesis, IL-l 
production and cell surface expression of MHC class II antigens. Its inhibitory 
effects on antigen processing/presentation are noL reversed by IL-l, IL-6 or anti-
CD28, suggesting that neither inhibition of production of these cytokines nor 
impairment of signalling via the B7 /CD28 pathway accounts for the immunosup-
pressive action of DSG. Apart from influencing monocytes/macrophages, DSG 
also inhibits the in vivo generation of cytotoxic T cells, either directly or indirectly. 
It has little effect on IL-2 or IFN-y production. On the other hand, the recovery 
of secondary cytotoxic T-cell activity (that is susceptible to DSG) following the 
addition of IFN-y, suggests that suppression of IFN-y production may be the 
main effect of DSG on T-cell populations. 
CLINICAL TRIALS WITH NEW IMMUNOSUPPRESSIVE DRUGS (FK506, 
MYCOPHENOLATE MOFETIL AND DSG) 
(i) FK506 
Clinical trials will be referred to here only briefly. FK506 was first used in clinical 
organ (liver) transplantation at the University of Pittsburgh Medical Center 
(UPMC) in February 1989. There have since been numerous reports from this 
center concerning its efficacy and safety, predominantly in human liver transplan-
tation, and also as primary immunosuppressive therapy in kidney, heart, lung 
and intestinal transplantation (Starzl et ai. 1989, 1991). FKS06 also shows a 
remarkable ability (unlike CsA) to reverse ongoing established liver, kidney or 
heart rejection. These single-center clinical trials showed FK506 to provide base-
line immunosuppressive therapy which was more potent than that achieved with 
CsA. Recently, the results of multi-center prospective randomized trials com-
paring FK506 to CsA after primary liver transplantation have been reported. The 
results of the US multi-center trial have shown that FKS06 plus corticosteroids is 
more efTective than CsA-based immunosuppressive regimens for prophylactic 
immunosuppression (McDiarmid et ai. 1993). The FKS06-treated group experi-
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enced significant reductions in the frequency and severity of rejection with less 
cumulative intravenous corticosteroid treatment. The side efTects of FK506 and 
CsA are similar, however, with each drug having the capacity to induce nephro-
toxicity, diabetogenicity or neurotoxicity. The incidence of post-transplant 
lymphoproliferative disease and the incidence of CMV infection is similar in 
FK506- and CsA-treated patients. 
One way of assessing the impact of a new immunosuppressive drug is to 
examine its influence on the transplantation of organs which has proved difficult 
to achieve using conventional immunosuppressants, including CsA. Thus, human 
liver transplantation rapidly became a practical clinical service with the advent 
of CsA. Until recently, death or graft loss after clinical intestinal transplantation 
was usually the result offailure to control rejection and/ or the inability to prevent 
immunological attack on the host by graft lymphoid tissue (graft-versus-host 
disease). In animal small bowel transplant models, FK506 has provided results 
superior to those obtained with CsA (Murase et al. 1990, 1991). prompting a 
clinical small bowel transplant trial. At the UPMC, small bowel allografts have 
been transplanted alone, together with liver, or in a small number of cases as 
part of a multivisceral cluster (Todo et al. 1992). In a study of 28 patients, 82% 
were alive at a median follow-up of 9 months. Graft survival was 76% after the 
same period and graft function was satisfactory, with 84°;{, of survivors showing 
complete enteral sufficiency and the other l6'/c, depending on supplemental par-
enteral nutrition. Rejection of the intestinal graft was common, with 90% of 
patients experiencing at least one episode. These patients have been treated with 
additional corticosteroids and azathioprine. Anti-lymphocyte preparations have 
also been used occasionally (Fung et al. 1993). 
Improved results using FK506 compared to CsA (each in combination with 
azathioprine) in a small prospective randomized trial of primary adult lung 
transplantation have also been achieved at the UPMC (Fung et a1. 1993). Six-
month graft survival and freedom from rejection were significantly greater in the 
FK506-treated group. Preliminary results have also been obtained using FK506 
in human autoimmune diseases (Thomson & Starzl 1992, Thomson et al. I 993a). 
Ongoing and future clinical trials using FK506 together with other conventional 
or experimental immunosuppressive agents may permit the further improvement 
of immunosuppressive drug regimens. 
(ii) Mycophenolate rnofeti! 
RS-61443 (Mycophenolate mofetil; MM) has been used adjunctively with CsA 
and prednisone in clinical renal transplantation. The results of two trials, a phase-
I dosage trial and a rescue trial have been reported (Sollinger et al. 1991, 1992). 
Dosages of MM from 100 mg/day to 3500/day have been Llsed with good 
tolerance and safely. Less rejection was seen at higher doses. The rescue trial 
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surveyed 20 cases of refractory kidney rejection under conventional therapy and 
found an 80°/c, response to MM in doses of 2-3.5 g/day. No evidence of nephro-, 
neuro-, hepato- or myelotoxicity was seen. In view of the relative safety and 
efficacy of MM in these preliminary trials, at multicenter randomized trial com-
paring CsA, MM, and prednisone with CsA, azathioprine, and prednisone has 
commenced. 
(iii) Deoxyspergualin (DSG) 
DSG has been used in several clinical studies in Japan to treat refractory kidney 
rejection and is effective either alone or when given with steroids (Amemiya et 
a!. 1990, 1991). A response rate ranging from 70-87% has been reported, and 
was over 90% when DSG and steroids were used together. DSG has also been 
used for induction therapy, in combination with CsA-based regimens and has been 
sllccessful in cadaveric, living-related, ABO-incompatible, and highly sensitized 
transplant recipients (for references, see Suzuki 1993). Excellent patient and graft 
survival have been reported, as well as less rejection and nephrotoxicity. Use of 
DSG in combination immunosuppressive therapy has also proved successful in 
achieving insulin independence in 2 recently reported cases of human pancreatic 
islet cell transplantation at the University of Minneapolis (Gores et a!. 1993). 
THE CHALLENGE OF XENOTRANSPLANTATTON 
Prolongation of organ xenograft survival with CsA or FK506 together with an 
antiproliferative agent 
Traditional immunosuppressive therapies have had limited success in preventing 
the rejection of experimental organ xenografts. Thus, drugs such as CsA and 
FK506 that are highly effective in inhibiting the predominantly cellular responses 
that are responsible for allograft rejection fail to prolong the survival of concord-
ant hamster-to-rat cardiac xenografts beyond 3-4 days (Gudas et a!. 1989, Van 
den Bogaerde et a!. 1991). In this rodent model, antibody and complement have 
been shown to be the primary mediators of graft rejection. Debilitating therapies, 
such as the combination of CsA with total lymphoid irradiation and monoclonal 
anti-CD4 antibody, however, can permit the survival of hamster-to-rat xenografts 
for several months, but this approach has very limited clinical application. Re-
cently, it has been shown that the combination of cyclophosphamide (Cy) with 
CsA or FK506 (but not Cy alone) can lead to prolonged (> 100 day) cardiac 
xenograft survival, with associated suppression of anti-hamster antibody produc-
tion (Hasan et a!. 1992, Murase et a!. 1993). Serious morbidity, however, due to 
infection consequent upon excessive immunosuppression, remains a potential 
problem with the combination of these powerful anti-T and anti-B cell agents. 
In a recent baboon-lo-human liver xenotransplantation, FK506 and Cy were 
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used as immunosuppressants, together with prednisone and prostaglandin (PGE) 
(Starzl et a1. 1993d). This combination was effective in preventing both the 
cellular and antibody-mediated rejection described earlier in baboon-to-human 
xenografts. 
IMMUNOSUPPRESSIVE DRUGS AND DONOR-DERIVED CELL CHIMERISM 
FOLLOWING ORGAN TRANSPLANTATION 
(iJ The phenomenon: migration of donor cells from graft to recipient 
Improvements in the immunosuppressive therapy of organ allograft rejection 
achieved using CsA and FK506 have been attributed to the potent and precise 
molecular actions of these drugs in inhibiting signal transduction in alloactivated 
T cells. There is now convincing evidence, however, that following organ trans-
plantation the promotion of peripheral T-cell tolerance to alloantigens by these 
and other biochemically diverse drugs may be associated, just as significantly. 
with a permissive effect of each drug on two-way (donor-recipient) leukocyte 
migration (Starzl et a1. 1992, 1993b). This leads to a state of mixed allogeneic 
cell microchimerism in both graft and host. 
It has recently been proposed that this cellular chimerism is a natural conse-
quence of organ transplantation under cover of immunosuppressive drug therapy 
(Starzl et a1. 1992, 1993b). Moreover. it is conceivable that donor-derived leuko-
cytes in the periphery of chimeras may play an important role in achieving and 
maintaining allotolerance, as many recent reports show that mature T cells can 
be tolerized after encountering antigen outside the thymus. In humans, the cell 
chimerism observed following organ transplantation may persist for many years 
even in patients who have discontinued all forms of immunosuppressive drug 
therapy (Starzl et a1. 1993c). In these studies, there has been no indication of 
drug specificity as the chimeric state was induced under azathioprine, Cy, CsA or 
FK506-based protocols, with additional immune modulation by corticosteroids, 
antilymphocyte antibodies, splenectomy or even thymectomy. Whether they were 
on or off maintenance immunosuppressive therapy, essentially all of the patients 
tested using in vitro mixed lymphocyte reaction or cell-mediated lymphocytotoxic-
ity methods exhibited some element of donor-specific nonreactivity. The variable 
ability of different transplanted organs to produce chimerism and. consequently. 
to induce such narrow nonreactivity, was explained by their comparative content 
of migratory leukocytes, believed to be greatest in the liver. 
These clinical studies indicated that cell migration and subsequent chimerism 
might be an integral requirement for organ graft acceptance, as well as the seminal 
step in tolerance induction. There was, however, a paucity of information about 
the events between the actual transplant and the above observations on chimerism 
made years later. Information which has helped to fill this gap has been provided 
by studies in the rat (Demetris et a1. 1993). 
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Although cell migration now appears to be a generic phenomenon following 
the transplantation of all organs, the rat liver transplant model was selected 
because the comparatively large volume of cell traffic to and from this organ is 
ideal for the study of the participating cells. The results have demonstrated that 
both the acute leukocyte migration and the ensuing long-term chimerism are 
probably multilineage. Donor T and B lymphocytes, as well as macrophages and 
dendritic cells from the transplanted liver were found to localize quickly in the 
lymph nodes, spleen and thymus of the recipient. Band T cells homed to 
appropriate B- and T-dependent areas. The traffic routes thus appeared similar 
to those utilized by phenotypically identical recipient cells. For the first 3 to 
S days post-transplant, these patterns were similar with or without systemic 
immunosuppressive drug (FKS06) therapy. After a further few days, however, 
the emigrant donor cells disappeared in the untreated recipients. 
In contrast, in the rat liver graft recipients immunosuppressed with a 28-day 
course of FKS06, the various donor cells persisted in the sites expected of 
phenotypically identical recipient lymphoid organs. In addition, a ubiquitous 
spread was evident after 2 to 4 weeks, with donor cells evident in the skin 
and heart - in the same way as after bone marrow and allogeneic fetal liver 
transplantation. Thereafter, the process proceeded and was sustained without the 
need for intensive maintenance immunosuppressive therapy, or in the absence of 
all further treatment. 
(ii) The common efleet of immunosuppressive drugs: a permissive eflect on 
leukocyte migration 
Both these clinical and experimental studies indicate that after organ transplan-
tation a variety of potentially immunogenic and/ or tolerogenic signals may be 
delivered to all of the lymphoid organs and then throughout the recipient by 
donor leukocytes. The consequences are dramatically different in untreated versus 
immunosuppressive drug-treated animals and the ultimate therapeutic effect is 
obviously not defined by any specific drug action alone. Thus it is common for 
the introduction of every potent new immunosuppressant to be followed by 
claims of tolerance induction in experimental animals. This is defined by the 
permanent acceptance of organ grafts after a short course of immunosuppression 
and without the need for further treatment or with minimal maintenance therapy. 
The precise site of immunosuppressive drug action does not appear to be 
crucial whether this be at the level of antigen presentation (DSG), cytokine 
gene transcription (FKS06 or esA), interdiction of cytokine action (rapamycin), 
or prevention of clonal expansion by drugs that inhibit DNA synthesis (azathio-
prine, mizoribine, or BQR) (Fig. 4). Notably, this generalization also applies to 
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F(f;lIre 4. Sites of action or immunosuppressive drugs and monoclonal antibodies (mAb) 
which have the capacity to induce tolerance to organ allografts in experimental animals. 
Common to all of the drugs shown is the ability to (ultimately) inhibit T-cell proliferation. 
Monoclonal antibodies which can induce tolerance in animals include non T cell-depleting 
anti-CD4 and anti-LFA-I +anti-ICAM-I antibodies. DSG=dcoxyspergualin; APC=anti-
gen-presenting cell; TH=T helper cell; IL-2R=interleukin-2 receptor. 
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monoclonal antibodies directed against cell surface antigens involved in critical 
cell recognition and interaction events. 
We have postulated (Starzl et al. 1993a) that the common influence of each of 
these diverse agents is a permissive effect, allowing the establishment of cell 
chimerism and the consequent body-wide "engagement" of donor and recipient 
cells. The chimerism in this hypothesis may be the cause of variable nonreactivity 
involving the donor/host relationship. The manner by which this nonreactivity 
occurs remains speculative, but it is clear that the alteration affects both the 
reactivity of the recipient immune system towards the passenger leukocytes and 
the converse. 
(iii) Mechanistic concepts 
Generation of a T-cell-mediated immune response leading normally to graft 
destruction requires, in its initial phase, effective antigen presentation and recog-
nition together with receipt of a second co-stimulatory signal and the response 
of T helper 1 (TH1 ) cells to the combined signal (Mueller et a1. 1989). Each of 
these signals is usually delivered to T cells by professional antigen-presenting cells 
(APC), including (activated) B cells and, above all, by dendritic cells that are 
prominent in the migration patterns both in the experimental animal studies and 
the human observations. The dendritic cell (and perhaps other cells, in particular 
B cells) may be critical because it can modify the expression of MHC, ceJl 
interaction and adhesion molecules - all of which determine how antigenic signals 
are heeded by T cells, It has been speculated that unperturbed dendritic cells 
present in non-lymphoid organs may have tolerizing potential (i.e. they may 
express MHC products but not the additional accessory/immunizing functions 
(Steinman et a1. 1993). Unless activated, B cells appear to be unable to provide co-
stimulatory signals and can induce transplantation tolerance (Fuchs & Matzinger 
1992). 
In the absence of co-stimulatory factor activity, there is disruption of the 
IL-2-IL-2R autocrine pathway. In in vitro culture systems, T H)-cell anergy is 
defined as a defect in IL-2 synthesis and proliferation in response to antigen 
restimulation. Specific defects in tyrosine phosphorylation pathways required 
for the induction of IL-2 synthesis may help explain antigen unresponsiveness 
in tolerant T cells (Cho et a1. 1993). Direct interference with the IL-2 induc-
tion pathway, using CsA or FK506 (both of which inhibit IL-2 gene transcrip-
tion) or mAb directed against IL-2 or the IL-2R, is highly effective in in-
ducing immune suppression and has profound implications for the induction 
of peripheral tolerance. It appears that in animals made tolerant by the in-
fusion of allogeneic leukocytes, there is normal IL-2 gene but low IL-2R gene 
induction. This may reflect abnormal translation control of IL-2 production 
(although no such regulation has previously been described for the IL-2 gene). 
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Figure 5. Model of APC-TH1-cell interaction, showing the production within the T-cell 
nucleus of positive (+) and of negative (-) regulators (anergy proteins) of IL-2 gene 
transcription. In this conceptual model, anergy relates only to the IL-2 gene and other 
cytokines (e.g. TFN-y) may be expressed, albeit at supoptimal levels. In the absence of 
persistent costimulatory signals (or under the umbrella of immunosuppressive drugs), cell 
division does not proceed and negative nuclear regula tors accumulate, resulting in T-cell 
anergy. In addition to the action of immunosuppressive agents, chronic antigen stimulation 
is also envisaged as promoting anergy. In some instances, tolerance can be broken, e.g. by 
administration of exogenous IL-2. HVG = host versus graft response (allograft rejection); 
GVHD = graft versus host disease. 
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It has been proposed (see, e.g. Jenkins 1992) that TCR occupancy leads to 
the production, through an active metabolic process, of negative regulators 
("anergy proteins") that accumulate at later times and repress IL-2 gene tran-
scription, possibly by antagonizing the effects of positive cytokine gene tran-
scription factors. In support of this hypothesis, T-cell specific negative regula-
tion of transcription of cytokine (IL-4) has recently been described. Moreover, 
a T-cell specific protein which can downregulate IL-4 promoter activity has 
been identified (Li-Weber et a!. 1992). There is also evidence of cellular pro-
tein binding to the negative regulatory elements of the IL-2R 2-chain gene 
(Smith & Greene 1989). Within murine anergic Till cell clones, this effect on 
cytokine gene expression may relate only to IL-2, as other cytokines, such as 
IL-3 or interferon-y (IFN-),), may be secreted, albeit at suboptimal levels. 
Under cover of potent immunosuppressive drugs which inhibit IL-2 produc-
tion (CsA or FK506) and in the continuous presence of (graft) alloantigens, 
it is likely that a chronically-stimulated T cell will continue to make negative 
regulators, thus reinforcing the state of anergy (Fig. 5). Anergic THI cells re-
main viable and can proliferate in response to exogenous IL-2. It is also poss-
ible that anergy can be induced in IL-2-producing T cells that receive both 
TCR and co-stimulatory signals, but are prevented from responding to IL-2 
or dividing by. e.g .. rapamycin (which blocks IL-2R-induced cell cycle S-phase 
entry) or leflunomide or inhibitors of DNA synthesis, such as mycophenolate 
mofetil (RS 61443) or BQR, respectively. Long-lasting antigen-specific anergy 
may ensue in a manner analogous to that observed in chronic microbial infec-
tion (Gaylord & Brennan 1987). 
SUMMARY 
Together with CsA. the new macrolide immunosuppressants FK506 and rapamy-
cin have proved to be valuable tools in providing new information about key 
molecular events that underlie lymphocyte activation and degranulation. Studies 
of their mechanisms of action have pinpointed the phosphatase caleineurin and 
protein kinases as important signaling mediators in T-cell activation. Other new 
immunosuppressive drugs, including let1unomide, mycophenolate mofetil, brequi-
naT sodium and deoxyspergualin exhibit diverse inhibitory effects on cells of 
the immune system and offer considerable promise as adjunctive therapeutic 
immunosuppressants. FK506 appears to be both a valuable therapeutic alterna-
tive to liver or kidney retransplantation and an alternative primary immunosup-
pressant to CsA in hepatic (especially) and renal transplantation. There is now 
good evidence that immunosuppressive drugs, both old and new, permit the 
establishment of donor-derived, multi-lineage cell chimerism following organ 
transplantation. 
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